Goldman Sachs Group Inc Aurinia Pharmaceuticals Inc. Transaction History

Goldman Sachs Group Inc

$780 Billion
Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 842,027 shares of AUPH stock, worth $12.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

842,027

Previous 439,020 91.8%

Holding current value

$12.9 Million

Previous $3.72 Million 150.24%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$7.47 - $13.14 $3.01 Million - $5.3 Million	403,007 Added 91.8%	842,027 $9.3 Million
Q2 2025 Aug 14, 2025	SELL	$7.2 - $8.64 $8.59 Million - $10.3 Million	-1,192,462 Reduced 73.09%	439,020 $3.72 Million
Q1 2025 May 09, 2025	SELL	$7.55 - $8.77 $911,224 - $1.06 Million	-120,692 Reduced 6.89%	1,631,482 $13.1 Million
Q4 2024 Feb 11, 2025	SELL	$6.75 - $10.44 $4.43 Million - $6.85 Million	-655,847 Reduced 27.24%	1,752,174 $15.7 Million
Q3 2024 Nov 14, 2024	BUY	$5.32 - $7.33 $815,896 - $1.12 Million	153,364 Added 6.8%	2,408,021 $17.7 Million

Q2 2024 Aug 13, 2024	BUY	$4.81 - $5.78 $493,039 - $592,467	102,503 Added 4.76%	2,254,657 $12.9 Million
Q1 2024 May 15, 2024	BUY	$4.93 - $9.31 $511,231 - $965,428	103,698 Added 5.06%	2,152,154 $10.8 Million
Q4 2023 Feb 13, 2024	BUY	$7.13 - $9.49 $4.11 Million - $5.47 Million	576,120 Added 39.13%	2,048,456 $18.4 Million
Q3 2023 May 14, 2024	SELL	$7.77 - $12.27 $4.48 Million - $7.07 Million	-576,120 Reduced 28.12%	1,472,336 $11.4 Million
Q3 2023 Nov 14, 2023	SELL	$7.77 - $12.27 $2.11 Million - $3.34 Million	-271,869 Reduced 15.59%	1,472,336 $11.4 Million
Q2 2023 May 14, 2024	BUY	$8.96 - $11.69 $6.76 Million - $8.82 Million	754,631 Added 76.26%	1,744,205 $16.9 Million
Q2 2023 Aug 14, 2023	BUY	$8.96 - $11.69 $6.76 Million - $8.82 Million	754,631 Added 76.26%	1,744,205 $16.9 Million
Q1 2023 May 14, 2024	BUY	$5.94 - $11.27 $3.08 Million - $5.85 Million	518,861 Added 110.23%	989,574 $10.8 Million
Q1 2023 May 11, 2023	BUY	$5.94 - $11.27 $3.08 Million - $5.85 Million	518,861 Added 110.23%	989,574 $10.8 Million
Q4 2022 May 14, 2024	SELL	$4.11 - $8.14 $14,495 - $28,709	-3,527 Reduced 0.74%	470,713 $2.03 Million
Q4 2022 Feb 13, 2023	SELL	$4.11 - $8.14 $14,495 - $28,709	-3,527 Reduced 0.74%	470,713 $2.03 Million
Q3 2022 May 14, 2024	SELL	$6.66 - $12.39 $1.64 Million - $3.05 Million	-246,194 Reduced 34.17%	474,240 $3.57 Million
Q3 2022 Nov 10, 2022	SELL	$6.66 - $12.39 $1.64 Million - $3.05 Million	-246,194 Reduced 34.17%	474,240 $3.57 Million
Q2 2022 May 14, 2024	SELL	$8.95 - $12.8 $11.9 Million - $17 Million	-1,328,022 Reduced 64.83%	720,434 $7.24 Million
Q2 2022 Aug 15, 2022	BUY	$8.95 - $12.8 $3.68 Million - $5.26 Million	410,727 Added 132.62%	720,434 $7.24 Million
Q1 2022 May 16, 2022	BUY	$10.05 - $22.48 $364,664 - $815,686	36,285 Added 13.27%	309,707 $3.83 Million
Q4 2021 Feb 14, 2022	BUY	$17.78 - $33.08 $1.73 Million - $3.22 Million	97,377 Added 55.31%	273,422 $6.25 Million
Q3 2021 Nov 10, 2021	BUY	$10.93 - $23.55 $1.92 Million - $4.15 Million	176,045 New	176,045 $3.9 Million

Others Institutions Holding AUPH

# of Institutions

269

Shares Held

69.3M

Call Options Held

984K

Put Options Held

574K

View Full List

About Aurinia Pharmaceuticals Inc.

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $2.18B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

More about AUPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Aurinia Pharmaceuticals Inc. Transaction History